A Multigene Score based on gene-expression profiling as a prognostic tool in women with early stage, hormone receptor-positive/Her2-negative breast cancer
Benedetta Conte(Ospedale Policlinico San Martino), Lucia Del Mastro(Ospedale Policlinico San Martino), Francesca Poggio(Ospedale Policlinico San Martino), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Bárbara Cardinali(Ospedale Policlinico San Martino), Claudia Bighin(Azienda Ospedaliera S.Maria), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Filippo Montemurro(Roche (Switzerland)), Valentina Guarneri(Istituto Oncologico Veneto), Nicla La Verde(ASST Fatebenefratelli Sacco), Ulrich Pfeffer(Ospedale Policlinico San Martino), Andrea Rocca(University of Trieste), Giancarlo Bisagni, A. Ferzi, M. Giordano, Matteo Lambertini(Ospedale Policlinico San Martino), F. Cognetti(Sapienza University of Rome), Laura Amaducci(Ospedale degli Infermi), E. Rota Caremoli(Ospedale Papa Giovanni XXIII), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 0
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Cancer and fertility preservation: international recommendations from an expert meeting
|BMC Medicine|2016|779